AI Terminal
Oxford Biomedica PLC
Report Publication Announcement • Aug 25, 2022
5190_rns_2022-08-25_c8698635-8ced-41cb-84a8-bfc8ec22b509.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1464X
Oxford Biomedica PLC
25 August 2022
Notice of Interim Results
Oxford, UK - 25 August 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2022 on Thursday 15 September 2022.
A virtual briefing for analysts will be held at 13:00 BST / 08.00 ET on the day of the results with a Q&A session. The webcast and conference call details will be made available on the Company's website at www.oxb.com. A replay of the presentation will be made available shortly afterwards.
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary-Jane Elliott / Matthew Cole / Angela Gray
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORFZLLLLVLBBBB